SCHEMBL14809449

SCHEMBL14809449

Cn1c(CO)c(-c2ccc(Cl)cc2)c2ccn(Cc3ccccc3)c2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
TP53 P04637 1/20 0.43
DPP4 P27487 3/20 0.43
LMNA P02545 3/20 0.42
HTT P42858 1/20 0.42
VEGFA P15692 2/20 0.42
EGLN1 Q9GZT9 2/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 1/20 0.41
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
ADORA2B P29275 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
HPGD P15428 1/20 0.38
BRD4 O60885 1/20 0.38
MAPK1 P28482 1/20 0.37
DHPS P49366 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14823818 0.89 ALOX5 (0.42) MAPTTP53DPP4LMNAHTT
SCHEMBL14809992 0.86 KDM4E (0.44) MAPTTP53DPP4LMNAHTT
SCHEMBL14809866 0.86 L3MBTL1 (0.42) MAPTTP53DPP4LMNAHTT
SCHEMBL14810427 0.83 MAPT (0.39) MAPTTP53DPP4LMNAHTT
SCHEMBL14809673 0.81 MAPK8 (0.52) MAPTTP53VEGFAEGLN1ALDH1A1
SCHEMBL18779897 0.78 MDM2 (0.37) MAPTTP53DPP4LMNAPOLB
SCHEMBL14809540 0.78 EGLN1 (0.39) MAPTTP53LMNAHTTVEGFA
SCHEMBL14809136 0.76 MAPT (0.37) MAPTTP53LMNAHTTVEGFA
SCHEMBL14809783 0.74 EGLN1 (0.36) MAPTTP53LMNAHTTVEGFA
SCHEMBL8787724 0.72 DPP4 (0.77) MAPTDPP4LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2757887-B1 PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV VIIV HEALTHCARE UK LTD (GB) 2017-04-26 EP disclosed
EP-2757887-B1 PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV VIIV HEALTHCARE UK LTD (GB) 2017-04-26 EP disclosed
US-9012642-B2 Pyrrolopyridinone compounds and methods for treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2015-04-21 US disclosed
US-9012642-B2 Pyrrolopyridinone compounds and methods for treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2015-04-21 US disclosed
US-9012642-B2 Pyrrolopyridinone compounds and methods for treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2015-04-21 US disclosed
US-20140343092-A1 Pyrrolopyridinone Compounds And Methods For Treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2014-11-20 US disclosed
US-20140343092-A1 Pyrrolopyridinone Compounds And Methods For Treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2014-11-20 US disclosed
US-20140343092-A1 Pyrrolopyridinone Compounds And Methods For Treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2014-11-20 US disclosed
EP-2757887-A1 PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV VIIV Healthcare UK Limited (GB) 2014-07-30 EP disclosed
WO-2013043553-A1 PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV GLAXOSMITHKLINE LLC (US) 2013-03-28 WO disclosed
WO-2013043553-A1 PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV GLAXOSMITHKLINE LLC (US) 2013-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343092-A1 Pyrrolopyridinone Compounds And Methods For Treating HIV DHPS, PRNP, TYMP MAPT 1289/4885TP53 1070/4885DPP4 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.